Neauvia PEGylated HA Fillers Study Wins NextGen Dermatology Award at IMCAS 2025!
We are thrilled to announce that Dr. Meryem Özlem Özturk, whose groundbreaking research on the safety of Neauvia’s PEGylated HA fillers in renal transplant patients, was awarded the prestigious NextGen Dermatology Award at IMCAS 2025. This recognition marks a significant milestone in Dr. Özlem Özturk’s academic and clinical journey, and serves as a powerful testament to the safety and reliability of Neauvia’s PEGylated HA fillers in sensitive patient populations.
The NextGen Dermatology module at IMCAS is a distinguished platform where young dermatologists present innovative research. Among the top five finalists, Dr. Meryem Özlem Özturk was awarded first place, emphasizing the importance of this accomplishment. The research demonstrated that Neauvia’s Intense fillers could be safely applied to renal transplant patients without a statistically significant increase in side effects compared to the general population.
The study, conducted over nearly a year of data collection, meticulously monitored the outcomes of Neauvia’s PEG-HA fillers in this sensitive patient group. Dr. Özlem Özturk highlighted that Neauvia’s PEGylated HA fillers are well-known for their superior safety profile, making them an ideal choice for treating vulnerable populations like renal transplant patients.
The success of this study would not have been possible without the support of the Neauvia Turkey team. This teamwork further strengthens Neauvia’s global recognition and solidifies its reputation for providing high-quality, scientifically backed solutions.
Dr. Meryem Özlem Özturk’s success does not end at IMCAS 2025. She has also been selected as a finalist in the Aesthetic Disruptor module at AMWC 2025 in Monaco. This achievement provides another platform to present this research on an international stage, with the opportunity to win another prestigious title.
We are proud of Dr. Meryem Özlem Özturk’s accomplishments and remain committed to advancing the field of aesthetics medicine. This recognition at IMCAS 2025 is a testament to our dedication to clinical excellence, scientific innovation, and patient safety.